Title |
Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial
|
---|---|
Published in |
Trials, October 2013
|
DOI | 10.1186/1745-6215-14-317 |
Pubmed ID | |
Authors |
Suk Jae Kim, Gyeong Joon Moon, Won Hyuk Chang, Yun-Hee Kim, Oh Young Bang, For the STARTING-2 (STem cell Application Researches and Trials In NeuroloGy-2) collaborators |
Abstract |
Recovery after a major stroke is usually limited, but cell therapy for patients with fixed neurologic deficits is emerging. Several recent clinical trials have investigated mesenchymal stem cell (MSC) therapy for patients with ischemic stroke. We previously reported the results of a controlled trial on the application of autologous MSCs in patients with ischemic stroke with a long-term follow-up of up to 5 years (the 'STem cell Application Researches and Trials In NeuroloGy' (STARTING) study). The results from this pilot trial are challenging, but also raise important issues. In addition, there have been recent efforts to improve the safety and efficacy of MSC therapy for stroke. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 2% |
Japan | 1 | <1% |
United States | 1 | <1% |
Unknown | 127 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 17% |
Student > Bachelor | 20 | 15% |
Student > Postgraduate | 14 | 11% |
Student > Ph. D. Student | 13 | 10% |
Student > Master | 11 | 8% |
Other | 22 | 17% |
Unknown | 29 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 38 | 29% |
Agricultural and Biological Sciences | 18 | 14% |
Neuroscience | 10 | 8% |
Biochemistry, Genetics and Molecular Biology | 9 | 7% |
Nursing and Health Professions | 3 | 2% |
Other | 19 | 15% |
Unknown | 34 | 26% |